Ligand Pharmaceuticals LGND Return on equity

Return on equity at other companies

Royalty PharmaRPRX

8.5%-2.2pp

Roivant SciencesROIV

-17.1%-17.7pp

Relay Therapeutics, Inc.RLAY

-36.8%-6.3pp

Ionis PharmaceuticalsIONS

-105.5%+336pp

Innoviva, Inc.INVA

29.1%—

Rigel PharmaceuticalsRIGL

174.1%—

FAQ

What is Ligand Pharmaceuticals's return on equity?

Ligand Pharmaceuticals (LGND) reported return on equity of 22% in Q2 2026.

How has Ligand Pharmaceuticals's return on equity changed year-over-year?

Ligand Pharmaceuticals's return on equity increased by 332.1% year-over-year, from -9.5% to 22%.

What is the long-term trend for Ligand Pharmaceuticals's return on equity?

Over 5 years (2020 to 2025), Ligand Pharmaceuticals's return on equity has grown at a 101.6% compound annual growth rate (CAGR), from -0.4% to 13.5%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.